Document Detail


Combretastatin (CA)-4 and its novel analogue CA-432 impair T-cell migration through the Rho/ROCK signalling pathway.
MedLine Citation:
PMID:  25450669     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
The capacity of T-lymphocytes to migrate and localise in tissues is important in their protective function against infectious agents, however, the ability of these cells to infiltrate the tumour microenvironment is a major contributing factor in the development of cancer. T-cell migration requires ligand (ICAM-1)/integrin (LFA-1) interaction, activating intracellular signalling pathways which result in a distinct polarised morphology, with an actin-rich lamellipodium and microtubule (MT)-rich uropod. Combretastatin (CA)-4 is a MT-destabilising agent that possesses potent anti-tumour properties. In this study, the effect of CA-4 and its novel analogue CA-432 on human T-cell migration was assessed. Cellular pretreatment with either of CA compounds inhibited the migration and chemotaxis of the T-cell line HuT-78 and primary peripheral blood lymphocyte (PBL) T-cells. This migration-inhibitory effect of CA compounds was due to the disruption of the MT network of T-cells through tubulin depolymerisation, reduced tubulin acetylation and decreased MT stability. In addition, both CA compounds induced the RhoA/RhoA associated kinase (ROCK) signalling pathway, leading to the phosphorylation of myosin light chain (MLC). Furthermore, the siRNA-mediated depletion of GEF-H1, a MT-associated nucleotide exchange factor that activates RhoA upon release from MTs, in T-cells prevented CA-induced phosphorylation of MLC and attenuated the formation of actin-rich membrane protrusions and cell contractility. These results suggest an important role for a GEF-H1/RhoA/ROCK/MLC signalling axis in mediating CA-induced contractility of T-cells. Therapeutic agents that target cytoskeletal proteins and are effective in inhibiting cell migration may open new avenues in the treatment of cancer and metastasis.
Authors:
Jade K Pollock; Navin K Verma; Niamh M O'Boyle; Miriam Carr; Mary J Meegan; Daniela M Zisterer
Related Documents :
25422029 - Cytotoxic constituents of abutilon indicum leaves against u87mg human glioblastoma cells.
25374189 - Anti-csc effects in human esophageal squamous cell carcinomas and eca109/9706 cells ind...
22529119 - Utility of nuclear morphometry in the cytologic evaluation of canine cutaneous soft tis...
25310629 - Geldanamycin mediates the apoptosis of gastric carcinoma cells through inhibition of ep...
25270259 - Association of the ef-hand and ph domains of the guanine nucleotide exchange factor sla...
21353719 - 5-aminolevulinic acid-induced fluorescence diagnosis of pleural malignant tumor.
20566339 - Diethyl sulfate induced cdk2-dependent centrosome amplification in chl cells.
21529069 - Toward label-free raman-activated cell sorting of cardiomyocytes derived from human emb...
8607839 - Heat shock protein synthesis and trehalose accumulation are not required for induced th...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-10-22
Journal Detail:
Title:  Biochemical pharmacology     Volume:  92     ISSN:  1873-2968     ISO Abbreviation:  Biochem. Pharmacol.     Publication Date:  2014 Oct 
Date Detail:
Created Date:  2014-12-2     Completed Date:  -     Revised Date:  2014-12-3    
Medline Journal Info:
Nlm Unique ID:  0101032     Medline TA:  Biochem Pharmacol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  544-557     Citation Subset:  -    
Copyright Information:
Copyright © 2014 Elsevier Inc. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Identification of a novel partial agonist of liver X receptor ? (LXR?) via screening.
Next Document:  Human ATP-Binding Cassette transporters ABCB1 and ABCG2 confer resistance to CUDC-101, a multi-actin...